A NAD infusion is often discussed in relation to energy, recovery, cognitive performance and healthy ageing. Those aims are understandable, particularly for people dealing with persistent fatigue or demanding schedules, but they should not be confused with established clinical outcomes. NAD+ intravenous therapy requires the same careful assessment, consent and governance as any other IV treatment.
NAD, short for nicotinamide adenine dinucleotide, is a coenzyme found naturally in every cell. It has a central role in cellular energy metabolism and supports enzymes involved in processes such as DNA repair and cell signalling. Interest in NAD+ has grown substantially, but biological plausibility is not, on its own, proof that intravenous administration delivers meaningful health benefits for a particular person.
What a NAD infusion involves
A NAD infusion delivers a prepared NAD+ solution into a vein through a cannula, usually over a prolonged period. The pace of administration matters. Some people find NAD+ uncomfortable if infused too quickly, reporting symptoms such as nausea, abdominal cramping, chest tightness, flushing, headache or a sense of anxiety. A suitably trained clinician should be able to adjust the rate, pause treatment and assess symptoms promptly.
This is not a standard hydration infusion. It should therefore not be approached as a routine add-on to a wellness appointment. Before treatment, a clinician should take a relevant medical history, discuss current medicines and supplements, check for factors that may affect IV safety, and explain what the infusion can and cannot reasonably be expected to do.
The practical experience varies. Appointment length depends on the prescribed dose, formulation, infusion rate and the individual’s tolerance. A responsible provider will avoid presenting a faster or higher-dose protocol as inherently better. Comfort and safety take priority over completing an infusion to a timetable.
Evidence for NAD infusion: what is known
Research into NAD biology is active and scientifically interesting. NAD+ is involved in fundamental cellular pathways, and studies continue to examine how NAD-related interventions may affect metabolism, ageing and neurological function. However, the evidence base for NAD+ administered by IV infusion in generally well people remains limited.
Available studies are often small, preliminary or focused on specific clinical contexts. They do not establish that NAD infusion reliably treats fatigue, burnout, addiction, cognitive decline, chronic illness or the effects of ageing. Claims that it can “reset” the body, reverse ageing or provide a guaranteed improvement in energy or mental clarity go beyond what current evidence can support.
That does not mean every individual experience is invalid. Some people report subjective benefits following treatment, while others notice little change or find the process unpleasant. The point is that personal reports cannot predict an outcome or replace well-designed clinical research. Expectations should remain proportionate, especially where tiredness, poor concentration or low mood may have an underlying medical, psychological or lifestyle cause requiring assessment.
For healthcare professionals and clinic operators, this distinction is central. Information provided before treatment should clearly separate established facts about NAD’s role in the body from unproven claims about IV NAD+ as a treatment. Marketing should not imply disease prevention, cure or treatment without appropriate evidence and regulatory basis.
Who should consider clinical assessment first?
Persistent fatigue is not a diagnosis. It can be associated with sleep disruption, iron deficiency, thyroid disease, diabetes, infection, medication effects, depression, anxiety and many other causes. New, severe or worsening symptoms, unexplained weight change, breathlessness, palpitations, fever, neurological symptoms or reduced ability to function warrant medical assessment rather than a wellness-focused infusion.
A NAD infusion may also be unsuitable, or require particular caution, for people with certain health conditions. The assessment should account for cardiovascular and kidney health, fluid balance, allergies, pregnancy or breastfeeding, previous difficulties with IV treatment, and current prescribed medicines or supplements. The relevance of each factor depends on the person and the proposed treatment plan.
A clinic should not use a short questionnaire as a substitute for a meaningful consultation. It should have a clear route for declining treatment, deferring treatment pending GP or specialist input, or escalating concerns if symptoms suggest an urgent medical issue.
Risks are not limited to the ingredient
Any IV procedure carries procedural risks, even when the solution itself is well tolerated. These include pain or bruising at the insertion site, failed cannulation, inflammation of the vein, infiltration of fluid into surrounding tissue, bleeding, infection and, rarely, more serious reactions. The likelihood of harm is influenced by the quality of assessment, aseptic technique, staff training, equipment, monitoring and emergency preparedness.
NAD+ itself may cause uncomfortable symptoms during administration, particularly when the rate is too rapid. This is one reason that self-administration, informal settings and protocols that encourage pushing through significant symptoms are not appropriate. Symptoms should be taken seriously, documented and managed by a clinician working within their competence.
Informed consent should be a conversation, not simply a signed form. Patients should receive clear information about the intended purpose, uncertainty of benefit, likely duration, possible adverse effects, alternatives and what follow-up is available if they feel unwell after leaving the clinic.
What safe provision looks like in the UK
Choosing a provider involves more than checking reviews or looking for a polished treatment menu. In the UK, patients should be able to identify who is clinically responsible for their care and understand the qualifications, professional registration and scope of practice of the staff involved.
A well-governed NAD+ service will have written protocols covering assessment, prescribing or patient-specific directions where required, product sourcing, storage, administration, observations, adverse-event management and record keeping. It should maintain appropriate infection prevention procedures and ensure emergency equipment, medicines and escalation processes are available and understood by staff.
The product itself deserves scrutiny. Patients should be told what is being administered, why it has been selected, and whether its use is licensed or otherwise prescribed and supplied within an appropriate clinical framework. Transparency is especially important where a product may not have a UK marketing authorisation for the intended use. A clinician should be able to explain this clearly, without minimising its relevance.
For clinic operators, governance also includes incident reporting, audit, staff competency assessment, insurance arrangements and appropriate data protection. Good practice is not defined by the most elaborate protocol. It is defined by whether the service can demonstrate safe decision-making consistently, including when the right outcome is to advise against treatment.
Questions worth asking before booking
Before arranging a NAD infusion, ask who will assess you and who will administer the treatment. Clarify the expected infusion duration, the common symptoms that can occur during administration, how the rate is adjusted, and what happens if you feel unwell.
It is also reasonable to ask how the clinic sources and stores the product, whether it has a written adverse-reaction protocol, and whether it will provide a record of what was given. If the answers are vague, overly promotional or dismissive of risk, consider that a warning sign.
Cost should be discussed plainly as well. A higher price does not prove superior quality, and a package of multiple infusions is not automatically clinically appropriate. Treatment frequency should be based on an individual assessment and transparent discussion, not pressure to commit in advance.
A measured decision is the safer decision
NAD infusion is an area of growing public interest, but its popularity should not be mistaken for certainty. For people considering it, the most useful starting point is a clinician who can assess the wider picture, explain the limits of evidence and put safety ahead of sales. For providers, careful governance and honest communication are not barriers to quality care – they are the foundation of it.